Hospital
UCSF Health Community Hospitals
UCSF Health Community Hospitals was paid $14.95M by Medicaid between Jan 2018 and Dec 2024, across 101 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 15% of everything it billed.
33Billing provider infoUCSF HEALTH COMMUNITY HOSPITALS
SAN FRANCISCO, CA 94109
SAN FRANCISCO, CA 94109
33aNPI1316061997assigned 03/19/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.95M
24GClaims211,594
24DCodes billed101
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#150 of 410
Median peer was paid$6.90M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40,088 | $1.53M | |
| 2019 | 38,663 | $1.52M | |
| 2020 | 28,083 | $1.95M | |
| 2021 | 28,602 | $2.54M | |
| 2022 | 23,145 | $2.22M | |
| 2023 | 32,330 | $3.13M | |
| 2024incomplete | 20,683 | $2.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 15% | 31,939 | 25,726 | $2.26M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 8,648 | 7,696 | $2.05M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.7% | 7,737 | 6,837 | $1.45M |
| A9150 | Non-prescription drugs | 9.6% | 4,842 | 2,301 | $1.44M |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 6.7% | 28,871 | 14,873 | $1.00M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.2% | 960 | 918 | $782K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.8% | 4,513 | 4,261 | $563K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.5% | 2,813 | 2,712 | $520K |
| 0450 | Emergency room services | 3.0% | 5,392 | 4,759 | $454K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.2% | 2,087 | 2,014 | $334K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.2% | 1,543 | 1,513 | $322K |
| 80053 | Comprehensive metabolic panel | 2.0% | 8,187 | 7,600 | $300K |
89 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 4,095 | $261K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 7,969 | $250K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 1,602 | $243K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 586 | $213K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 1,467 | $207K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 4,893 | $204K |
| Z7502 | 1.4% | 5,311 | $204K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 2,827 | $191K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 4,166 | $189K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 1,597 | $179K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,068 | $149K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,078 | $103K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,510 | $93K |
| 82962 | <1% | 2,453 | $81K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,277 | $72K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,576 | $65K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,718 | $61K |
| J3490 | Unclassified drugs | <1% | 4,917 | $57K |
| 84484 | <1% | 3,703 | $56K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 500 | $37K |
| 99070 | <1% | 2,009 | $37K | |
| 83880 | <1% | 921 | $33K | |
| 83605 | <1% | 2,056 | $32K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 359 | $27K |
| 90715 | <1% | 617 | $26K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,352 | $26K |
| 16020 | <1% | 1,446 | $26K | |
| 83690 | <1% | 2,742 | $24K | |
| 87040 | <1% | 1,096 | $23K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,550 | $21K |
| 81001 | <1% | 3,311 | $20K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 56 | $19K |
| 0270 | <1% | 1,537 | $19K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 328 | $18K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,072 | $17K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,986 | $16K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 315 | $15K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,201 | $11K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 125 | $11K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 77 | $10K |
| 81025 | <1% | 1,176 | $10K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,371 | $10K |
| 81003 | <1% | 918 | $9K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 417 | $8K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 95 | $8K |
| 83735 | <1% | 537 | $6K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 747 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 576 | $6K |
| 73562 | <1% | 108 | $5K | |
| A9270 | Non-covered item or service | <1% | 2,599 | $5K |
| J1815 | Injection, insulin, per 5 units | <1% | 15 | $4K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 136 | $4K |
| 85610 | <1% | 750 | $3K | |
| Z7610 | <1% | 731 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 72 | $3K |
| 93971 | <1% | 12 | $3K | |
| 10060 | <1% | 97 | $2K | |
| 87186 | <1% | 179 | $2K | |
| 0949 | <1% | 67 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 94 | $2K |
| 96367 | <1% | 27 | $2K | |
| 73130 | <1% | 40 | $2K | |
| 99199 | Unlisted special service, procedure or report | <1% | 41 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 54 | $2K |
| 80047 | <1% | 50 | $2K | |
| 87631 | <1% | 18 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 94 | $1K |
| 87077 | <1% | 27 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 67 | $1K |
| 82550 | <1% | 207 | $847.23 | |
| 73502 | <1% | 14 | $786.67 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 123 | $780.75 |
| 84703 | <1% | 112 | $756.32 | |
| Z7500 | <1% | 20 | $682.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 624 | $651.72 |
| 71010 | <1% | 50 | $552.36 | |
| 71020 | <1% | 35 | $547.27 | |
| 85379 | <1% | 45 | $525.38 | |
| 73630 | <1% | 12 | $502.31 | |
| 80061 | Lipid panel | <1% | 16 | $370.56 |
| 73030 | <1% | 13 | $365.47 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 56 | $348.32 |
| 87081 | <1% | 38 | $316.58 | |
| 73610 | <1% | 13 | $254.23 | |
| J2358 | Injection, olanzapine, long-acting, 1 mg | <1% | 31 | $199.24 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 27 | $186.42 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 13 | $162.06 |
| 87430 | <1% | 13 | $145.58 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 16 | $58.18 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORENO, FERNANDO (CFO/DIRECTOR)
Parent organizationUCSF HEALTH COMMUNITY HOSPITALS
| Provider | Location | Paid |
|---|---|---|
| UCSF Health Community Hospitals | San Francisco, CA | $7.40M |
| UCSF Health Community Hospitals | San Francisco, CA | $256K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.